Topical Ketorolac Tromethamine in the Reduction of Adverse Effects of Laser in Situ Keratomileusist
PANIDA KOSRIRUKVONGS, M.D.*, SABONG SRIV ANNABOON, M.D.*, PINNITA PRABHASAWAT,M.D.*, KANOGRAT PORNPANICH, M.D.*
Affiliation : * Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. t Presented at 71h annual meeting of the Royal College of Ophthalmologists of Thailand at Cha-am, Petchburi on July 16, 2000. Supported by Siriraj Excimer Laser Center, Bangkok, Thailand.
Purpose : To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK).
Design : A prospective randomized controlled clinical study. Participants : Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital.
Intervention : Patients received two drops of ketorolac tromethamine in one eye imme diately after surgery.
Main outcome measures : Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours.
Results : There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes.
Conclusions : Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.
Keywords : Laser in Situ Keratomileusis, Topical Ketorolac Tromethamine
